292 related articles for article (PubMed ID: 22936711)
1. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.
Hoeper MM; Halank M; Wilkens H; Günther A; Weimann G; Gebert I; Leuchte HH; Behr J
Eur Respir J; 2013 Apr; 41(4):853-60. PubMed ID: 22936711
[TBL] [Abstract][Full Text] [Related]
2. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
Rubin LJ; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh A; Langleben D; Fritsch A; Menezes F; Davie N; Ghofrani HA
Eur Respir J; 2015 May; 45(5):1303-13. PubMed ID: 25614164
[TBL] [Abstract][Full Text] [Related]
3. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
[TBL] [Abstract][Full Text] [Related]
4. Riociguat: a novel new drug for treatment of pulmonary hypertension.
Makowski CT; Rissmiller RW; Bullington WM
Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
[TBL] [Abstract][Full Text] [Related]
5. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Marra AM; Egenlauf B; Ehlken N; Fischer C; Eichstaedt C; Nagel C; Bossone E; Cittadini A; Halank M; Gall H; Olsson KM; Lange TJ; Grünig E
Int J Cardiol; 2015 Sep; 195():19-26. PubMed ID: 26011408
[TBL] [Abstract][Full Text] [Related]
6. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
Simonneau G; D'Armini AM; Ghofrani HA; Grimminger F; Hoeper MM; Jansa P; Kim NH; Wang C; Wilkins MR; Fritsch A; Davie N; Colorado P; Mayer E
Eur Respir J; 2015 May; 45(5):1293-302. PubMed ID: 25395036
[TBL] [Abstract][Full Text] [Related]
7. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.
Grimminger F; Weimann G; Frey R; Voswinckel R; Thamm M; Bölkow D; Weissmann N; Mück W; Unger S; Wensing G; Schermuly RT; Ghofrani HA
Eur Respir J; 2009 Apr; 33(4):785-92. PubMed ID: 19129292
[TBL] [Abstract][Full Text] [Related]
8. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
Ghofrani HA; Hoeper MM; Halank M; Meyer FJ; Staehler G; Behr J; Ewert R; Weimann G; Grimminger F
Eur Respir J; 2010 Oct; 36(4):792-9. PubMed ID: 20530034
[TBL] [Abstract][Full Text] [Related]
9. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F
Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
[TBL] [Abstract][Full Text] [Related]
10. Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study.
D'Armini AM; Ghofrani HA; Kim NH; Mayer E; Morsolini M; Pulido-Zamudio T; Simonneau G; Wilkins MR; Curram J; Davie N; Hoeper MM
J Heart Lung Transplant; 2015 Mar; 34(3):348-55. PubMed ID: 25813765
[TBL] [Abstract][Full Text] [Related]
11. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
12. Riociguat for the treatment of pulmonary arterial hypertension.
Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
[TBL] [Abstract][Full Text] [Related]
13. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
14. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
[TBL] [Abstract][Full Text] [Related]
15. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
Simonneau G; D'Armini AM; Ghofrani HA; Grimminger F; Jansa P; Kim NH; Mayer E; Pulido T; Wang C; Colorado P; Fritsch A; Meier C; Nikkho S; Hoeper MM
Lancet Respir Med; 2016 May; 4(5):372-80. PubMed ID: 27067478
[TBL] [Abstract][Full Text] [Related]
16. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
Ghofrani HA; Grimminger F; Grünig E; Huang Y; Jansa P; Jing ZC; Kilpatrick D; Langleben D; Rosenkranz S; Menezes F; Fritsch A; Nikkho S; Humbert M
Lancet Respir Med; 2016 May; 4(5):361-71. PubMed ID: 27067479
[TBL] [Abstract][Full Text] [Related]
17. [Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].
Leuchte HH; Behr J; Ewert R; Ghofrani HA; Grünig E; Halank M; Held M; Klose H; Rosenkranz S; Schermuly RT; Wilkens H; Hoeper MM
Pneumologie; 2015 Mar; 69(3):135-43. PubMed ID: 25750094
[TBL] [Abstract][Full Text] [Related]
18. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
Bonderman D; Ghio S; Felix SB; Ghofrani HA; Michelakis E; Mitrovic V; Oudiz RJ; Boateng F; Scalise AV; Roessig L; Semigran MJ;
Circulation; 2013 Jul; 128(5):502-11. PubMed ID: 23775260
[TBL] [Abstract][Full Text] [Related]
19. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Belik J
Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
[TBL] [Abstract][Full Text] [Related]
20. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.
Nathan SD; Behr J; Collard HR; Cottin V; Hoeper MM; Martinez FJ; Corte TJ; Keogh AM; Leuchte H; Mogulkoc N; Ulrich S; Wuyts WA; Yao Z; Boateng F; Wells AU
Lancet Respir Med; 2019 Sep; 7(9):780-790. PubMed ID: 31416769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
